Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users

AIDS

Volumn 24, Issue 14, 2010, Pages 2151-2160

  Tomescu, Costin ^a   Duh, Fuh Mei ^b,c   Lanier, Michael A ^d   Kapalko, Angela ^e   Mounzer, Karam C ^e   Martin, Maureen P ^b,c   Carrington, Mary ^b,c   Metzger, David S ^d   Montaner, Luis J ^a  

^a WISTAR INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Philadelphia Fight   (United States)

Author keywords

Exposed Uninfected; HIV AIDS; IDU; NK cells; plasmacytoid DC

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; HLA B ANTIGEN; HLA BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GENOTYPE; HIGH RISK BEHAVIOR; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INNATE IMMUNITY; INTRAVENOUS DRUG ABUSE; MALE; NATURAL KILLER CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL;

ADULT; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; PHILADELPHIA; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77956225105     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833dfc20     Document Type: Article

References (44)

1. Muller-Trutwin M, Hosmalin A. Role for plasmacytoid dendritic cells in anti-HIV innate immunity. Immunol Cell Biol 2005; 83:578-583.
2. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibitpulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006; 203:1153-1159.
3. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, Nakano A, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005; 202:425-435.
4. Bandyopadhyay S, Perussia B, Trinchieri G, Miller DS, Starr SE. Requirement for HLA-DRR accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med 1986; 164: 180-195.
5. Feldman M, Howell D, Fitzgerald-Bocarsly P. Interferon-alpha-dependent and-independent participation of accessory cells in natural killer cell-mediated lysis of HSV-1-infected fibroblasts. J Leukoc Biol 1992; 52:473-482.
6. Fitzgerald-Bocarsly P, Feldman M, Curl S, Schnell J, Denny T. Positively selected Leu-11a (CD16R) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji. J Immunol 1989; 143:1318-1326.
7. Oh SH, Bandyopadhyay S, Miller DS, Starr SE. Cooperation between CD16(Leu-11b)R NK cells and HLA-DRR cells in natural killing of herpesvirus-infected fibroblasts. J Immunol 1987; 139:2799-2802.
8. Perussia B, Fanning V, Trinchieri G. A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses. Nat Immun Cell Growth Regul 1985; 4:120-137.
9. Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007; 179:2097-2104.
10. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181:203-214.
11. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, Rojo S, et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997; 155:135-144.
12. Boyton RJ, Altmann DM. Natural killer cells, killer immuno-globulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007; 149:1-8.
13. R T cell response against HIV-1. PLoS Med 2006; 3:e403.
14. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740.
15. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
16. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, Simic N, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-BM57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
17. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22:595-599.
18. Boileau C, Bruneau J, Al-Nachawati H, Lamothe F, Vincelette J. A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials. J Acquir Immune Defic Syndr 2005; 39:489-495.
19. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.
20. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3R/CD56R cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006: 120:138-146.
21. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos MA, Gray GE, et al. Cutting edge: unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182:5914-5918.
22. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
23. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 2009; 86:132-154.
24. City of Philadelphia Department of Public Health. Philadelphia integrated epidemiological profile. Edited by Department of Public Health. Philadelphia: Office of HIV Planning; 2009.
25. Williams CT, Metzger DS. Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health 2010; 100:1068-1074.
26. Metraux S, Metzger DS, Culhane DP. Homelessness and HIV risk behaviors among injection drug users. J Urban Health 2004; 81:618-629.
27. Martin MP, Carrington M. KIR locus polymorphisms: genotyp-ing and disease association analysis. Methods Mol Biol 2008; 415:49-64.
28. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305.
29. Ballan WM, Vu BA, Long BR, Loo CP, Michaelsson J, Barbour JD, et al. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007; 179:3362-3370.
30. Tomescu C, Chehimi J, Maino VC, Montaner LJ. Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation. J Leukoc Biol 2009; 85:871-876.
31. Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:1179-1188.
32. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med 2005; 172:530-551.
33. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasma-cytoid dendritic cells. Eur J Immunol 2001; 31:2154-2163.
34. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170:4465-4474.
35. Schroeder JT, Bieneman AP, Xiao H, Chichester KL, Vasagar K, Saini S, Liu MC. TLR9-and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 2005; 175:5724-5731.
36. Averill L, Lee WM, Karandikar NJ. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol 2007; 123:40-49.
37. Kanto T, Inoue M, Miyazaki M, Itose I, Miyatake H, Sakakibara M, et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 2006; 49:58-63.
38. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42:61-67.
39. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 2004; 40:335-345.
40. Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie 1992; 47:503-512.
41. Ugen KE, Nyland SB. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy. Springer Semin Immunopathol 2006; 28:281-287.
42. Zhang T, Li Y, Ho WZ. Drug abuse, innate immunity and hepatitis C virus. Rev Med Virol 2006; 16:311-327.
43. Weed MR, Carruth LM, Adams RJ, Ator NA, Hienz RD. Morphine withdrawal dramatically reduces lymphocytes in morphine-dependent macaques. J Neuroimmune Pharmacol 2006; 1:250-259.
44. Saurer TB, Carrigan KA, Ijames SG, Lysle DT. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. J Neuroimmunol 2006; 173:3-11.